Ensysce Biosciences Releases 2021 Annual Shareholder Letter

May 5, 2022 5:15 PM

SAN DIEGO, CA / ACCESSWIRE / May 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the release of its 2021 Annual Shareholder Letter authored by Chief Executive Officer, Dr. Lynn Kirkpatrick. To view the letter...

Read more

Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University

May 5, 2022 8:30 AM

The licensed technology was jointly invented by researchers at Case Western Reserve University and Dartmouth CollegeThe license covers the use of plant viruses such as cowpea mosaic virus (CPMV) for the treatment of cancer in both human and companion animalsNOVATO, CA / ACCESSWIRE / May 5, 2022 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and...

Read more

Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

May 4, 2022 8:00 AM

VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that its CEO, Sean Carrick, was recently interviewed by Proactive Investors (ProactiveInvestors.com), providing a brief history of Nascent Biotech as well as fresh...

Read more

Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022

May 4, 2022 8:00 AM

BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2022 investor call on Wednesday, May 11, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.To...

Read more

HeathTech for Care: Applications are Now Open for European Innovative Healthcare Companies for the 4th Edition of the HealthTech Innovation Days (13th & 14th, October 2022)

May 4, 2022 4:30 AM

PARIS, FRANCE / ACCESSWIRE / May 4, 2022 / The HealthTech Innovation Days (HTID®) event, held by the HealthTech For Care endowment fund, will take place on 13th and 14th October 2022 and will provide a forum for promising European life sciences companies to accelerate their growth and bring their solutions to patients more quickly. The 4th edition will take place in a hybrid format, in Paris, in the HealthTech space, and in virtual mode.The...

Read more

Apollo Endosurgery, Inc. Reports 33% U.S. Revenue Growth in First Quarter 2022

May 3, 2022 4:01 PM

Global revenue grew 20% year-over-year as adoption increased across all product linesAUSTIN, TX / ACCESSWIRE / May 3, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the first quarter ended March 31, 2022 and recent corporate highlights.First Quarter 2022 Selected Financial Results (Numbers in...

Read more

Thermic Science Reports Aggressive 2022 Growth Guidance, Thermic Tech New Product Launches, Cannabis Science Acquisition, Successful "Make That Change" Killing Cancer Challenge, 1 - Million Strong, American States University

May 3, 2022 8:40 AM

NASHVILLE, TN / ACCESSWIRE / May 3, 2022 / Thermic Science International Corporation, (OTC:ENDO), a U.S. an Advanced Technology Global Consortium, focused on providing key real-time, public access Digital HUB with advanced SaaS solutions. Focused on a hybrid mix of traditional real-world transactions online with real-time inter-connectivity tools for business and personal information and transactions.Thermic Science is pleased to report an...

Read more

CB Scientific, Inc. Welcomes James Ott as Chief Technology Officer

May 3, 2022 6:00 AM

Newly created position to spearhead technological innovation in the next stage of growthESCONDIDO, CA / ACCESSWIRE / May 3, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, today announces that effectively immediately James Ott has joined the Company's executive management team as its Chief Technology Officer. Mr. Ott...

Read more

BioInvent's BI-1206 to Advance into Expansion Stage of Phase 1/2a Study in NHL after a Productive End-of-Phase 1 FDA Meeting

May 3, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / May 3, 2022 / BioInvent International (STO:BINV)BI-1206 moving into expansion phase as plannedData presented so far include early signs of efficacyNext steps to include planning potentially pivotal Phase 2 studyLund, Sweden - May 3, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

Read more

enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 2, 2022 8:00 AM

- Ended the quarter with $51.3 million in cash - expected to fund operations through the end of 2024 including release of topline pivotal trial data- Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients- Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022IRVINE, CA / ACCESSWIRE / May 2, 2022 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or...

Read more

HAVN Life Sciences Inc. to Present at the Planet MicroCap Showcase 2022 in Las Vegas on Wednesday, May 4, 2022

April 30, 2022 8:00 AM

VANCOUVER, BC / ACCESSWIRE / April 30, 2022 / HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE:5NP), a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, today announced that it will be presenting at the Planet MicroCap Showcase 2022 at the Bally's Hotel & Casino in Las Vegas, NV on Wednesday, May 4, 2022 at 9:00...

Read more

Biovica Completes 510(k) Submission for DiviTum(R)TKa to the FDA

April 28, 2022 12:15 PM

UPPSALA, SE / ACCESSWIRE / April 28, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)Biovica, active in cancer diagnostics, today announces that the company has submitted its updated 510(k)-application to the U.S. Food and Drug Administration (FDA) to receive marketing authorization for the blood-based biomarker assay DiviTum®TKa.Biovica's complete submission addresses the deficiencies identified by the agency on Biovica's...

Read more

Resolutions at BioInvent's Annual General Meeting 2022

April 28, 2022 11:30 AM

LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV)The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) resolved to re-elect the Board members Kristoffer Bissessar, Dharminder Chahal, Thomas Hecht, Leonard Kruimer, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program.The AGM voted in favor of adopting the income statements and balance...

Read more

Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

April 28, 2022 7:45 AM

Completion of enrollment is anticipated by calendar fourth quarter for the Phase 2b study of Edesa's potentially first-in-class, anti-inflammatory drugTORONTO, ON / ACCESSWIRE / April 28, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that patient recruitment for a Phase 2b clinical study evaluating the company's drug candidate, designated...

Read more

BioInvent Receives Milestone Payment from Bayer/Hope Medicine Licensing Agreement

April 28, 2022 2:55 AM

LUND, SWEDEN / ACCESSWIRE / April 28, 2022 / BioInvent International (STO:BINV)Lund, Sweden - April 28, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces that it receives a milestone payment following clinical progression of an out-licensed antibody.BioInvent receives EUR...

Read more

Biovica Capital Markets Day Invitation May 17, 2022

April 28, 2022 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / April 28, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)Biovica, active in cancer diagnostics, will host a Capital Markets Day on Tuesday May 17, 2022, from 14.00 to 16.30.Biovica is approaching market launch of DiviTum®TKa in the US for the monitoring of metastatic breast cancer treatments. Today, DiviTum®TKa is sold to pharmaceutical companies and academic institutions for use in...

Read more

Pressure BioSciences Announces Early Access Program for UST Nanoemulsion Processing

April 27, 2022 9:35 AM

Strong Market Demand Fuels Company's Decision to Access Early Revenue Generating Opportunities for UST Processing of High Quality Nanoemulsions of Oil-Based Active Ingredients for Multiple Markets Ahead of Q4 2022 Commercialization - Company Expects Several Executed Contracts During Q2 2022SOUTH EASTON, MA / ACCESSWIRE / April 27, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of...

Read more

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

April 27, 2022 6:30 AM

Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunityDNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indicationsXenetic plans to conduct a Phase 1 clinical study of lead asset in locally advanced or metastatic solid tumorsCompany to host update conference call and webcast...

Read more

BioInvent International AB: Interim Report January-March 2022

April 27, 2022 2:20 AM

LUND, SE / ACCESSWIRE / April 27, 2022 / BioInvent International (STO:BINV)"The exciting translational data presented on BI-1808 at AACR clearly show why we are so enthusiastic about our ongoing clinical studies in solid tumors. It is highly encouraging that we see similar biomarker correlations in patient samples as we observe in the preclinical setting."- Martin Welschof, CEO BioInvent.EVENTS IN THE FIRST QUARTER• (R) Orphan...

Read more

Midatech Pharma PLC Announces Results for the Year Ended 31 December 2021

April 26, 2022 2:00 AM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 26, 2022 / Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the year ended 31 December 2021.2021 HIGHLIGHTSOperational· In June 2021, in an R&D update we announced:o Breakthrough data on the successful encapsulation of a biologic using Q-Sphera...

Read more